Oral Semaglutide May Reduce Alcohol Use, CU Anschutz Trial Suggests
A clinical trial at the University of Colorado Anschutz found that oral semaglutide reduced heavy drinking days and alcohol-related harm in adults with Alcohol Use Disorder (AUD). The findings were published in late July 2026.
Researchers at the University of Colorado Anschutz have found that oral semaglutide, a medication known for treating diabetes and promoting weight loss, significantly reduced heavy drinking days and alcohol-related harm in adults diagnosed with Alcohol Use Disorder (AUD).
The clinical trial's results suggest that semaglutide could offer a new therapeutic avenue for managing alcohol dependence. Participants who received semaglutide experienced a notable decrease in the frequency of heavy drinking episodes compared to those who received a placebo. The study also indicated a reduction in the overall burden of alcohol-related harms among the treated group.
Semaglutide functions as a GLP-1 receptor agonist, a mechanism believed to influence brain reward pathways and appetite regulation. This action may contribute to its effects on cravings and addictive behaviors. While established for type 2 diabetes and chronic weight management, its potential applications are being explored in other addiction-related fields.
The findings contribute to the ongoing search for pharmacological interventions to address alcohol use disorder, a condition with currently limited effective treatment options. Further research will be necessary to fully validate semaglutide's efficacy and safety profile for AUD treatment.